Predicting patent challenges for small-molecule drugs: A cross-sectional study
Generic competition does not occur with the same timeliness across all drug markets, which can leave granted patents of questionable merit in place and sustain high brand-name drug prices. Predictive models may help direct limited resources for post-grant patent validity review and adjust policy when generic competition is lacking.
Authors
- Ally Memedovich
- Mina Tadrous (ORCID: https://orcid.org/0000-0003-1911-6129)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Brian Steele (ORCID: https://orcid.org/0000-0002-0081-1079)
- Aidan Hollis (ORCID: https://orcid.org/0000-0001-5125-2193)
- Reed F. Beall (ORCID: https://orcid.org/0000-0001-8188-7616)
- Shanzeh Chaudhry (ORCID: https://orcid.org/0009-0006-7838-8836)
- Taylor Orr
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Calgary (CA)
- University of Toronto (CA)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1371/journal.pmed.1004540
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- Commonwealth Fund
- Arnold Ventures
- Canada Research Chairs